B CELL RECEPTOR-INDUCED PHOSPHORYLATION OF PYK2 AND FOCAL ADHESION KINASE INVOLVES INTEGRINS AND THE RAP GTPases AND IS REQUIRED FOR B CELL SPREADING*
Kathy W.K. Tse‡, May Dang-Lawson‡, Rosaline L. Lee‡, Doris Vong‡, Anica Bulic‡, Leonard Buckbinder‡, and Michael R. Gold‡1

From ‡Department of Microbiology and Immunology and the I3 and CELL Research Groups, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, V6T 1Z3 Canada and Pfizer Global Research and Development, Groton, CT 06340 USA

Running head: Regulation of Pyk2 and FAK in B cells

Address correspondence to: Michael R. Gold, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. FAX: 604-822-6041; E-mail mgold@interchange.ubc.ca.

Signaling by the B cell receptor (BCR) promotes integrin-mediated adhesion and cytoskeletal reorganization. This results in B cell spreading, which enhances the ability of B cells to bind antigens and become activated. Proline-rich tyrosine kinase (Pyk2) and focal adhesion kinase (FAK) are related cytoplasmic tyrosine kinases that regulate cell adhesion, cell morphology, and cell migration. In this report we show that BCR signaling and integrin signaling collaborate to induce the phosphorylation of Pyk2 and FAK on key tyrosine residues, modifications that increase the kinase activity of Pyk2 and FAK. Activation of the Rap GTPases is critical for BCR-induced integrin activation as well as for BCR- and integrin-induced reorganization of the actin cytoskeleton. We now show that Rap activation is essential for BCR-induced phosphorylation of Pyk2 and for integrin-induced phosphorylation of Pyk2 and FAK. Moreover, Rap-dependent phosphorylation of Pyk2 and FAK required an intact actin cytoskeleton as well as actin dynamics, suggesting that Rap regulates Pyk2 and FAK via its effects on the actin cytoskeleton. Importantly, B cell spreading induced by BCR/integrin co-stimulation or by integrin engagement was inhibited by shRNA-mediated knockdown of either Pyk2 or FAK expression and by treatment with PF-431396, a chemical inhibitor that blocks the kinase activities of both Pyk2 and FAK. Thus Pyk2 and FAK are downstream targets of the Rap GTPases that play a key role in regulating B cell morphology.

Antibodies (Abs) made by B-lymphocytes play a critical role in host defense against infection. Antigen-induced signaling by the B cell receptor (BCR) initiates an activation program that leads to B cell proliferation and subsequent differentiation into Ab-producing cells. BCR clustering by antigens, or by anti-immunoglobulin (anti-Ig) Abs used as surrogate antigens, initiates multiple signaling pathways that control gene expression, cell survival, and proliferation pathways (1-3).

BCR signaling also promotes integrin activation (4,5), localized actin polymerization, reorganization of the actin cytoskeleton, and changes in B cell morphology (6,7), all of which may facilitate B cell activation. Integrin activation and cell spreading is critical for the activation of B cells by membrane-bound antigens. Macrophages, dendritic cells, and follicular dendritic cells (FDCs) can present arrays of captured antigens to B cells (8,9) and this may be one of the main ways in which B cells encounter antigens (10). BCR-induced integrin activation prolongs the interaction between the B cell and the antigen-presenting cell and also allows the B cell to spread on the surface of the antigen-presenting cell such that more BCRs can encounter and bind membrane-bound antigens (11). Subsequent contraction of the B cell membrane allows the B cells to gather the BCR-bound antigen into an immune synapse in which clustered antigen-engaged BCRs are surrounded by a ring of ligand-bound integrins. Formation of this immune synapse reduces the amount of antigen that is required for B cell activation (12,13).
Recent work has shown that B cells in lymphoid organs may contact soluble antigens by extending membrane processes into a highly organized network of lymph-filled conduits (14). These conduits are created by fibroblastic reticular cells (FRCs) that partially ensheath collagen fibrils. In addition to being rich in collagen, fibronectin, and other extracellular matrix (ECM) components, the FRCs that form these conduits express high levels of intercellular adhesion molecule-1 (ICAM-1), the ligand for the $\alpha_4\beta_2$ integrin (lymphocyte function-associated antigen-1, LFA-1) on B cells (10). Thus B cells interacting with these conduits are likely to be in contact with integrin ligands and integrin-dependent spreading may enhance the ability of B cells to extend membrane processes into the FRC conduit.

In addition to promoting cell spreading, integrins can act as co-stimulatory receptors that enhance signaling by many receptors including the T cell receptor (TCR) and the BCR (15-17). Thus signaling proteins that regulate B cell spreading, and which are also targets of BCR/integrin co-stimulation, may play a key role in the activation of B cells by membrane-bound antigens as well as soluble antigens that are delivered to lymphoid organs by FRC conduits.

Proline-rich tyrosine kinase (Pyk2) and focal adhesion kinase (FAK) are related non-receptor protein tyrosine kinases that integrate signals from multiple receptors and play an important role in regulating cell adhesion, cell morphology and cell migration in many cell types (18-20). Integrins, receptor tyrosine kinases, antigen receptors, and G protein-coupled chemokine receptors all stimulate tyrosine phosphorylation of Pyk2 and FAK, modifications that increase the enzymatic activity of these kinases and allow them to bind SH2 domain-containing signaling proteins (21). FAK, which is expressed in almost all tissues (21), is a focal adhesion component that mediates integrin-dependent cell migration (22), cell spreading, and cell adhesion (18) in adherent cells, as well as co-clustering of LFA-1 with the TCR in lymphocytes (23). Pyk2 is expressed mainly in hematopoietic cells, osteoclasts, and the central nervous system (24) and is critical for chemokine-induced migration of B cells, macrophages and natural killer cells (20,25,26), as well as the spreading of osteoclasts on vitronectin (27). FAK and Pyk2 are thought to mediate overlapping but distinct functions since Pyk2 expression only partially reverses the cell adhesion and migration defects in FAK-deficient fibroblasts (28).

In B cells, clustering of the BCR, $\beta_1$ integrins, or $\beta_2$ integrins induces tyrosine phosphorylation of both Pyk2 and FAK (29-33). FAK is involved in the chemokine-induced adhesion of B cell progenitors (34) and Pyk2 is required for chemokine-induced migration of mature B cells (25). However, the role of these kinases in BCR-and integrin-induced B cell spreading has not been investigated and the signaling pathways that link the BCR and integrins to tyrosine phosphorylation of Pyk2 and FAK have not been elucidated.

We have previously shown that the ability of the BCR to induce integrin activation, B cell spreading, and immune synapse formation requires activation of the Rap GTPases (6,17). In addition to binding effector proteins such as RapL and RIAM that promote integrin activation (35-37), the active GTP-bound forms of Rap1 and Rap2 bind multiple proteins that control actin dynamics and cell morphology (38). Moreover, we showed that BCR/integrin-induced phosphorylation of Pyk2 in B cells is dependent on Rap activation (17). However this previous study did not address how Rap-GTP links the BCR and integrins to Pyk2 phosphorylation, whether Rap activation is important for FAK phosphorylation in B cells, or whether B cell spreading is regulated by Pyk2 or FAK. We now show that Pyk2 and FAK are differentially expressed and localized in B cells, that Pyk2 and FAK are important for B cell spreading, and that integrin engagement enhances BCR-induced phosphorylation of Pyk2 and FAK, a process that depends on both Rap activation and actin dynamics.

**Experimental procedures**

**Antibodies and Inhibitors**—Goat and donkey anti-mouse IgG, as well as goat anti-mouse IgM, were from Jackson ImmunoResearch Laboratories (West Grove, PA). Rat monoclonal anti-LFA-1 (anti-$\alpha_4\beta_2$ integrin) and anti-CD40 (1C10) were from eBioscience (San Diego, CA). A rat monoclonal Ab against very late antigen-4 (anti-VLA-4; anti-$\alpha_4\beta_1$ integrin) was purified from culture supernatants of the PS/2 hybridoma (39) (from Dr. Bosco Chan, Univ. of Western Ontario, London,
Ontario, Canada). Rabbit anti-Erk, goat anti-Pyk2 (sc-1514), and goat anti-FAK (C-20) were from Santa Cruz Biotechnology (Santa Cruz, CA). The 4G10 monoclonal anti-phosphotyrosine (P-Tyr) Ab was from Upstate (Charlottesville, VA). Abs to Y397-, Y576-, and Y577-phosphorylated FAK and Y579/Y580-phosphorylated Pyk2 were from Biosource International (Camarillo, CA). The rabbit polyclonal Ab against Y402-phosphorylated Pyk2, the murine monoclonal Ab against phosphorylated Erk, and the rabbit monoclonal Ab against S473-phosphorylated Akt were from Cell Signaling Technology (Danvers, MA). The monoclonal Ab to paxillin was from BD Biosciences (Mississauga, Ontario, Canada). Horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz), goat anti-rabbit IgG (Bio-Rad, Hercules, CA), and goat-anti mouse IgG (GE Healthcare Bio-Sciences, Baie d’Urfe, Quebec, Canada) were used for immunoblotting. Latrunculin A and jasplakinolide were from Calbiochem (La Jolla, CA). PF-431396 has been described previously (40). The pCMV-ΔR8.91 and pCMV-VSV-G-M5 plasmids were a gift from Dorothee von Laer (Georg-Speyer Haus Chemotherapeutic Institute, Frankfurt, Germany).

Cells—B cells were isolated from the spleens of C57BL/6 mice using the MACS B cell isolation kit (Miltenyi Biotec, Auburn, CA) to deplete non-B cells (41). The resulting cells were >98% B cells, as determined by staining with anti-CD19-FITC (BD Pharmingen). Activated B cells were obtained by culturing splenic B cells with 25 μg/ml lipopolysaccharide (LPS, Sigma-Aldrich, St. Louis, MO) plus 5 ng/ml IL-4 (R&D Systems, Minneapolis, MN) for 2-3 days. A20 cells (ATCC, Manassas, VA) were maintained as previously described (17). Bulk populations of A20 cells stably transduced with the empty pMSCVpuro vector (BD Biosciences Clontech, Mountain View, CA) or with pMSCVpuro/RapGAPII have been described previously (17).

Expression of Pyk2 and FAK—For immunoblotting with Abs to Pyk2 or FAK, cells were solubilized in RIPA buffer (42). For quantitative RT-PCR, RNA was prepared using the RNeasy kit with QIAshredder columns (Qiagen, Valencia, CA) and converted into cDNA using the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). Equivalent amounts of cDNA were combined with TaqMan Fast Universal PCR Master Mix (Applied Biosystems) plus TaqMan Gene Expression Assay primers and probes (Applied Biosystems) specific for Pyk2 (Mm00552840_m1), FAK (Mm00433209_m1), or GAPDH (Mm99999915_g1). PCR reactions and quantitation were performed using an Applied Biosystems 7500 Fast Real-Time PCR system. The amount of pyk2 or fak mRNA was normalized to the amount of gapdh mRNA for each sample.

RT-PCR analysis of pyk2 mRNA splicing. PCR primers (5’-GTGGCCCTCTCTGAGTGTGT-3’, 5’-GATCTTCTCTGCTCCCAGA-3’) that flank the alternatively spliced exon of the mouse pyk2 gene were used to amplify cDNA from resting and activated mouse B cells. These primers amplify a 738 bp fragment from cDNA generated from unspliced Pyk2 mRNA and a 612 bp fragment from cDNA from the hematopoietic cell-specific Pyk2 isoform in which a 126 bp exon is deleted. PCR products were separated on 2% agarose gels and visualized with CyberSafe DNA gel stain.

Immunofluorescence—Cells were fixed with 3% paraformaldehyde for 20 min and then permeabilized with phosphate-buffered saline (PBS) plus 0.1% Tween-20 for 45 min. After blocking with PBS containing 2% bovine serum albumin for 10 min, the cells were stained with goat Abs to Pyk2 or FAK for 45 min, followed by Alexa488-conjugated donkey anti-goat IgG (Molecular Probes-Invitrogen, Eugene, OR) for 30 min. Where indicated, cells were also stained with rat monoclonal Abs to LFA-1 or VLA-4, followed by Alexa568-conjugated donkey anti-rat IgG (Molecular Probes-Invitrogen). The cells were washed and adhered to poly-L-lysine-coated coverslips, which were treated with Prolong Gold anti-fade reagent containing DAPI (Molecular Probes-Invitrogen) and mounted onto glass slides. Images were collected using an Olympus IX81/Fluoview1000 confocal microscope and processed using Olympus Fluoview 1.6 software.

Phosphorylation of Pyk2, FAK, Erk, Akt, and Paxillin—A20 cells or splenic B cells (1.5 x 10^7) in 1 ml modified HEPES-buffered saline (41) were
stimulated with anti-Ig Abs either while in suspension or 30 min after being added to wells of 6-well tissue culture plates coated with a collagen/fibronectin ECM (17,43). This ECM was generated by sequentially coating the wells with a 2% gelatin solution and then fetal calf serum. To initiate integrin signaling, cells were added to wells that had been coated with Abs to LFA-1 or VLA-4, as described (6). Reactions were terminated by adding 0.25 ml of cold 5X lysis buffer (17). After 10 min on ice, insoluble material was removed by centrifugation. Where indicated, aliquots of cell lysate were removed to assess total protein tyrosine phosphorylation or the phosphorylation of Erk, Akt, paxillin, Pyk2 and FAK were immunoprecipitated from cell lysates as described (34,41).

Short Hairpin RNA (shRNA)-mediated Knockdown of Pyk2 and FAK expression in A20 cells—pGIPZ lentiviral vectors encoding GFP as well as shRNAmir’s specific for murine Pyk2 (catalogue no. V2LMM_21947) or FAK (catalogue no. V2LMM_37327) were purchased from Open Biosystems (Huntsville, AL). Lentiviruses were generated by transfecting 293T cells with the appropriate lentiviral vector (7.5 μg) together with 12.5 μg of pCMV-ΔR8.91 and 2 μg of pCMV-VSV-G-M5 (44,45). Viral supernatants were collected 24 and 48 h after transfection and filtered through a 0.45 μm filter. A20 cells (6 x 10^5) were added to wells of a 6-well dish containing 3 ml of viral supernatant and then centrifuged at 2000 rpm for 1 h at 21°C. Cells were cultured with 5 μg/ml puromycin to select for transduced cells.

Cell Spreading—Tissue-culture plates were coated overnight at 4°C with a rat anti-mouse LFA-1 monoclonal Ab (6), or with fibronectin (R&D Systems, Minneapolis, MN), and then blocked with PBS containing 2% bovine serum albumin for 1 h. A20 cells (10^5 cells in 0.5 ml RPMI-1640 with 2% FCS and 50 μM 2-mercaptoethanol) were pre-treated with DMSO or PF-431396 for 45 min, added to the coated wells, and centrifuged at 2000 rpm for 1 h at 21°C. Cells were cultured with 5 μg/ml puromycin to select for transduced cells.

Rap Activation—Rap activation assays were performed as described (17). A GST-RalGDS fusion protein was used to selectively precipitate the active GTP-bound form of Rap, which was detected by immunoblotting with a Rap1 Ab (Santa Cruz Biotechnology).

Results

Expression and localization of Pyk2 and FAK in B cells — Because Pyk2 and FAK regulate cell morphology in many cell types, we asked whether both of these kinases were expressed in mature B cells from mouse spleen. Immunoblotting showed that resting B cells from mouse spleen expressed high levels of Pyk2 but only low levels of FAK (Fig. 1A). We also asked whether B cell activation altered the expression of Pyk2 or FAK since activated, but not resting, primary B cells undergo dramatic spreading when plated on integrin ligands or on immobilized Abs to CD44, CD23, or the BCR (46-48). Activating splenic B cells with LPS plus IL-4 for 2 days resulted in a 4- to 5-fold decrease in Pyk2 protein levels and a 6-fold increase in FAK levels (Fig. 1A). This likely reflects transcriptional regulation since a similar downregulation of pyk2 mRNA and upregulation of fak mRNA occurred upon B cell activation (Fig. 1B). A number of murine (WEHI-231, BAL17, A20) and human B lymphoma cell lines (Ramos, Daudi, Raji) expressed both Pyk2 and FAK (Fig. 1A and data not shown), consistent with that these cells representing transformed versions of activated B cells. We also observed that Pyk2 from LPS/IL-4 activated B cells ran as a doublet on SDS-PAGE gels (Fig. 1, A and C). The higher molecular weight form of Pyk2 may be the unspliced form that has been reported to be highly expressed in brain but not in the spleen (49). Indeed, RT-PCR showed that both the spliced and unspliced forms of pyk2 mRNA were present in activated B cells whereas only the spliced form was present in resting B cells (Fig. 1D). Both isoforms of the Pyk2 protein were tyrosine phosphorylated upon BCR clustering in activated splenic B cells (Fig. 1C).

Confocal microscopy showed that Pyk2 and FAK had distinct subcellular localizations in B cells (Fig. 1E). In both resting and activated murine splenic B cells, Pyk2 was uniformly distributed in the cytoplasm with a diffuse pattern. In contrast, FAK was present in punctate structures in both resting and activated splenic B cells.
cells (Fig. 1E), as well as the A20 B cell line (data not shown). Activated splenic B cells had more FAK-containing punctae than resting splenic B cells and overall, higher levels of FAK, consistent with the immunoblotting data. These punctate FAK-containing structures also contained LFA-1, and to some extent VLA-4 (α4β1 integrin) (Fig. 1F), suggesting that FAK associates constitutively with these integrins in B cells.

Adhesion to ECM enhances BCR-induced tyrosine phosphorylation of Pyk2 and FAK—To examine the role of Pyk2 and FAK in BCR and integrin signaling in B cells, we used the A20 B lymphoma cell line, which expresses both Pyk2 and FAK. Consistent with the idea that integrins can act as co-stimulatory receptors that enhance BCR signaling, we showed previously that BCR-induced tyrosine phosphorylation of Pyk2 is substantially greater when A20 cells are plated on a collagen/fibronectin ECM that contains integrin ligands than when the cells are stimulated in suspension (17) (see also Fig. 2A). As was the case for Pyk2, BCR-induced tyrosine phosphorylation of FAK was also substantially increased when A20 cells were plated on ECM (Fig. 2A). The binding of integrins to ECM ligands did not cause an overall enhancement of BCR signaling but selectively augmented BCR-induced tyrosine phosphorylation of FAK and Pyk2. BCR-induced serine/threonine phosphorylation of Erk, Akt, and the cytoskeleton-associated adaptor protein paxillin was not enhanced by integrin engagement (Fig. 2, B and C). The selective targeting of Pyk2 and FAK by BCR/integrin co-stimulation suggests that these kinases may be important for integrin-dependent B cell responses.

BCR/integrin-induced B cell spreading involves Pyk2 and FAK—A20 cells spread dramatically when they are plated on fibronectin and then stimulated with anti-Ig Abs (6,17). In this scenario BCR signaling activates β1 integrins (e.g. VLA-4), which bind to the fibronectin, and the combined BCR/integrin signaling leads to cell spreading. A20 cells also spread when plated on immobilized Abs that cluster the LFA-1 integrin, adopting a morphology similar to that of anti-Ig-activated A20 cells spreading on ICAM-1, the physiological ligand for LFA-1 (6). This indicates that integrin signaling is sufficient to induce B cell spreading. Because integrin signaling selectively enhances the ability of the BCR to induce tyrosine phosphorylation of Pyk2 and FAK (Fig. 2), and can independently induce the phosphorylation of these kinases (see Fig. 5), we asked whether Pyk2 or FAK played a role in B cell spreading.

To test this, we used RNA interference to reduce the expression of Pyk2 or FAK in A20 cells. We established stable bulk populations of A20 cells containing the GFP-encoding pGIPZ lentiviral vector or derivatives of this vector that also encode short hairpin RNAs (shRNAs) specific for either Pyk2 or FAK. The resulting cell populations were >95% GFP+ (Fig. 3A) and immunoblotting showed that the Pyk2 shRNA reduced the expression of Pyk2 by 83% without affecting FAK levels whereas the FAK shRNA reduced the expression of FAK by 67% without affecting Pyk2 levels (Fig. 3B). Knocking down the expression of either Pyk2 or FAK caused a 30-40% reduction in the number of A20 cells that developed a spread, elongated morphology when plated on fibronectin and then stimulated with anti-Ig Abs (Fig. 3C). The same was true when A20 cells were plated on immobilized anti-LFA-1 Abs (Fig. 3C). Thus Pyk2 and FAK both contribute to BCR/integrin- and integrin-induced B cell spreading in A20 cells.

BCR/integrin-induced tyrosine phosphorylation of Pyk2 and FAK depends on activation of the Rap GTPases—Because activation of the Rap GTPases is critical for BCR- and integrin-induced B cell spreading (6,17), and Pyk2 and FAK contribute to this process, we hypothesized that Rap activation would be important for BCR-induced tyrosine phosphorylation of Pyk2 and FAK. The phosphorylation of Pyk2 and FAK on conserved tyrosine residues increases their kinase activity (21,50). The initial event in receptor-induced activation of these kinases is phosphorylation of Pyk2 on Y402 or FAK on Y397. This is thought to occur via dimerization and transphosphorylation (51). Src family kinases (SFKs) can then bind via their SH2 domain to the phosphorylated Pyk2 Y402 or FAK Y397 and phosphorylate Pyk2 at Y579/Y580 or FAK at Y576/Y577. Phosphorylation of Pyk2 and FAK on these activation loop residues is required for maximal activity of these kinases towards
substrates (21). We showed previously that Rap activation is required for BCR/integrin-induced phosphorylation of Pyk2 on Y579/Y580 (17). However, it was not known whether this reflected a role for Rap activation in Y402 phosphorylation or the SFK-mediated phosphorylation of Y579/Y580. Moreover, the role of Rap activation in BCR/integrin-induced FAK phosphorylation had not been assessed.

To address these questions, we blocked Rap activation in A20 cells by expressing the Rap-specific GTPase-activating protein, RapGAPII (52). RapGAPII converts the Rap1 and Rap2 GTPases to their inactive GDP-bound state and RapGAPII expression has been widely used to assess the role of Rap activation (53, 54). We have shown that RapGAPII expression completely blocks anti-Ig-, chemokine- and phorbol ester-induced Rap activation in A20 cells, without inhibiting other signaling reactions such as phosphorylation of MAP kinases or Akt (17, 42).

Preventing Rap activation via RapGAPII expression significantly inhibited tyrosine phosphorylation of Pyk2 on Y402 when A20 cells were plated on ECM and stimulated with soluble anti-Ig antibodies (Fig. 4A). This corresponded with inhibition of total Pyk2 tyrosine phosphorylation, as assessed using anti-P-Tyr Abs (Fig. 4A). Thus BCR/integrin-induced phosphorylation of Pyk2 on Y402, the first step in Pyk2 activation is dependent on Rap activation. The same was true for FAK. The use of phosphorylation site-specific Abs showed that blocking Rap activation significantly inhibited BCR/integrin-induced phosphorylation of FAK on Y397 (Fig. 4B) as well as the subsequent phosphorylation of FAK on Y576/Y577 (Fig. 4C). Consistent with this, the total tyrosine phosphorylation of FAK, as detected using the 4G10 anti-P-Tyr Ab was also inhibited when Rap activation was blocked (Fig. 4B). Thus during BCR/integrin co-stimulation, Rap activation is critical for the initial step in the activation of Pyk2 and FAK, phosphorylation of Pyk2 on Y402 and FAK on Y397. As a consequence Rap activation is also required for the subsequent SFK-mediated phosphorylation of the activation loop tyrosine residues of Pyk2 and FAK.

The requirement for Rap activation in BCR/integrin co-stimulation-induced phosphorylation of Pyk2 and FAK could reflect a role for Rap activation in one or more of the following processes: coupling BCR signaling pathways to the phosphorylation of Pyk2 and FAK, activating integrins such that ligand binding initiates outside-in integrin signaling, or coupling integrin signaling pathways to the phosphorylation of Pyk2 and FAK. We have previously shown that Rap activation is essential for the BCR to stimulate integrin activation (17). Therefore we now investigated whether Rap activation was also an essential component of the signaling pathways that link the BCR and integrins to the phosphorylation of Pyk2 and FAK. Since integrin engagement greatly enhances BCR-induced phosphorylation of Pyk2 and FAK, we first tested the hypothesis that integrin signaling induces Pyk2 and FAK phosphorylation in a Rap-dependent manner.

**Rap activation is important for integrin-induced phosphorylation of Pyk2 and FAK**—In order to initiate integrin signaling without stimulating the cells through the BCR, we plated A20 cells on wells coated with Abs against the LFA-1 or VLA-4 integrins. We have previously shown that the ability of A20 cells to spread on immobilized anti-integrin Abs, or on immobilized ICAM-1, is dependent on Rap activation (6). Moreover, Ab-induced clustering of LFA-1 activates Rap1 in A20 cells (6). Figure 5A shows that plating A20 cells on wells coated with Abs to LFA-1 or VLA-4 resulted in increased Pyk2 phosphorylation, compared to cells plated on wells coated with an isotype-matched control monoclonal Ab against CD40. Both LFA-1- and VLA-4-induced Pyk2 phosphorylation were substantially reduced in the RapGAPII-expressing A20 cells in which Rap activation was blocked (Fig. 5A). Similarly, FAK phosphorylation, which was increased 3- to 4-fold by clustering VLA-4, and to a lesser extent by clustering LFA-1, was significantly reduced when Rap activation was blocked (Fig. 5B). Thus Rap activation is required for integrin signaling to induce tyrosine phosphorylation of Pyk2 and FAK.

**Rap activation is important for BCR-induced phosphorylation of Pyk2, but not for BCR-induced phosphorylation of FAK**—When A20 cells were stimulated with anti-Ig Abs while in suspension, BCR clustering induced tyrosine
phosphorylation of both Pyk2 and FAK, although to a much lesser extent than when the cells were plated on ECM (Fig. 2). Since integrin engagement is likely to be minimal when the cells are in suspension, this may reflect integrin-independent BCR signaling events. Therefore we asked whether Rap activation was important for integrin-independent phosphorylation of Pyk2 and FAK by the BCR. When we kept vector control and RapGAPII-expressing A20 cells in suspension and stimulated them with soluble anti-Ig Abs, blocking Rap activation completely abrogated BCR-induced phosphorylation of Pyk2 at Y402 and Y579/Y580 (Fig. 6A). In contrast, blocking Rap activation did not impair the ability of the BCR to increase tyrosine phosphorylation of FAK, as judged using the 4G10 anti-P-Tyr Ab, or more specifically, phosphorylation of FAK at Y397 (Fig. 6B). Thus both BCR-induced (Fig. 6A) and integrin-induced (Fig. 5A) Pyk2 phosphorylation required Rap activation whereas integrin-induced FAK phosphorylation was dependent on Rap activation (Fig. 5B) but BCR-induced FAK phosphorylation was Rap-independent (Fig. 6B).

The role of Rap activation in the phosphorylation of Pyk2 and FAK corresponds to a requirement for actin dynamics—Because Rap activation is required for maximal BCR-induced increases in polymerized F-actin in A20 cells (17), we hypothesized that Rap might regulate the phosphorylation of Pyk2 and FAK via its ability to promote actin polymerization or stabilize actin filaments. To test this, we pre-treated A20 cells with latrunculin A, a drug that prevents the addition of actin monomers to existing actin filaments, thereby leading to a loss of F-actin. Confocal microscopy showed that a 30 min treatment with latrunculin A led to a nearly complete loss of F-actin in A20 cells (data not shown). In the presence of latrunculin A, anti-Ig-induced phosphorylation of Pyk2 at Y402 and Y579/Y580 was almost completely blocked, both when the cells were stimulated in suspension and when they were stimulated while on ECM (Fig. 7A). Similar results were obtained using cytochalasin D (data not shown), another drug that leads to the loss of F-actin. An intact actin cytoskeleton was not required for other BCR signaling events such as phosphorylation of Erk or Akt (Fig. 7B). Importantly, latrunculin A did not block BCR-induced Rap1 activation (Fig. 7C), consistent with the idea that F-actin acts downstream of Rap activation to promote Pyk2 phosphorylation.

For FAK phosphorylation, the requirement for an intact actin cytoskeleton paralleled the requirement for Rap activation. When A20 cells were stimulated with anti-Ig while in suspension, BCR-induced FAK phosphorylation was unaffected by blocking Rap activation (Fig. 6B) or by disrupting the actin cytoskeleton with latrunculin A (Fig. 7D). In contrast, when the cells were stimulated while on ECM, BCR/integrin-induced FAK phosphorylation was significantly reduced by disrupting the actin cytoskeleton with latrunculin A (Fig. 7D) and by blocking Rap activation (Fig. 4B). Thus a Rap- and F-actin-dependent pathway links integrins, but not the BCR, to FAK phosphorylation.

The ability of latrunculin A and cytochalasin D to block BCR-induced Pyk2 phosphorylation could reflect a requirement for actin filaments, which may act as signaling platforms, or a requirement for the dynamic assembly and disassembly of actin filaments. To distinguish these possibilities, we used jasplakinolide, a drug that prevents actin filament disassembly (55). When A20 cells were stimulated in suspension, jasplakinolide treatment completely inhibited BCR-induced phosphorylation of Pyk2 while having no effect on BCR-induced Rap1 activation (Fig. 7E). Thus both disrupting actin filaments and stabilizing actin filaments inhibited the Rap-dependent phosphorylation of Pyk2 by the BCR. In contrast, BCR-induced phosphorylation of FAK in cells that were kept in suspension, did not require Rap activation and was unaffected by either latrunculin A (Fig. 7D) or jasplakinolide (Fig. 7E).

B cell spreading requires Pyk2/FAK kinase activity—We have shown that Rap activation is important for BCR/integrin-induced tyrosine phosphorylation of Pyk2 and FAK (Figs. 4 and 5) and for BCR- and integrin-induced B cell spreading (6,17). This suggests that activated Rap may promote B cell spreading, at least in part, by facilitating the phosphorylation-dependent activation of Pyk2 and FAK. Indeed, knocking down the expression of either Pyk2 or FAK reduced B cell spreading (Fig. 3C). To
specifically address the role of Pyk2 and FAK kinase activity in BCR/integrin-induced B cell spreading, we used PF-431396, a potent and highly selective pyrimidine-based inhibitor of both Pyk2 and FAK (40). Consistent with the idea that the tyrosine phosphorylation of Pyk2 and FAK involves an initial autophosphorylation or transphosphorylation step, treating A20 cells with PF-431396 blocked anti-Ig-induced tyrosine phosphorylation of Pyk2 and FAK when the cells were stimulated in suspension (Fig. 8A) and when they were stimulated on ECM (Fig. 8B). The phosphorylation of Pyk2 and FAK induced by clustering LFA-1 with plate-bound Abs was also inhibited by PF-431396 (Fig. 8B). PF-431396 treatment was not cytotoxic, as judged by 7-AAD staining (data not shown), and did not reduce the ability of the BCR to stimulate Erk phosphorylation or overall protein tyrosine phosphorylation (Fig. 8A), which is dependent on the activation of both SFKs and the Syk tyrosine kinase. Thus, PF-431396 appeared to selectively inhibit BCR-induced tyrosine phosphorylation or overall protein tyrosine phosphorylation (Fig. 8A), which is dependent on the activation of both SFKs and the Syk tyrosine kinase. Finally, we showed that both Rap activation and actin dynamics were critical for BCR/integrin-induced phosphorylation of Pyk2 and FAK.

We had previously shown that integrin engagement enhances BCR-induced Pyk2 phosphorylation (17) and we have now shown that the same is true for FAK phosphorylation. Moreover, by clustering integrins with Abs, we showed that integrin signaling was sufficient to induce tyrosine phosphorylation of Pyk2 and FAK in B cells. Thus signaling by antigen-clustered BCR complexes and ligand-bound integrins can have additive effects on the phosphorylation of Pyk2 and FAK. This highlights the ability of integrins to act as co-stimulatory receptors that collaborate with lymphocyte antigen receptors. Pyk2 and FAK appeared to be selective targets of the BCR/integrin collaboration as integrin engagement did not enhance BCR-induced phosphorylation of other signaling proteins such as Erk, Akt and paxillin.

We also showed that activation of the Rap GTPases was critical for BCR/integrin signaling to induce the phosphorylation of Pyk2 and FAK on their auto/transphosphorylation sites as well as tyrosine residues in their activation loops. Although Rap-GTP likely contributes to Pyk2 and FAK phosphorylation by activating integrins on B cells (17), we found that activated Rap also acts downstream of the BCR to promote Pyk2 phosphorylation and downstream of integrins to promote the phosphorylation of Pyk2 and FAK. The active GTP-bound form of Rap binds multiple effector proteins that promote actin polymerization and the stabilization of F-actin polymers (38). Many of the downstream consequences of Rap activation may therefore reflect its role in reorganization of the actin cytoskeleton. Indeed, we found that the Rap-dependent steps in Pyk2 and FAK phosphorylation were also blocked by actin-disrupting drugs. This suggests that Rap-GTP promotes Pyk2 and FAK phosphorylation via its ability to remodel the actin cytoskeleton. Rap1 activation was not dependent on actin dynamics, suggesting that the requirement for actin remodeling lies downstream of Rap activation.

Although Pyk2 phosphorylation has been shown to require an intact actin cytoskeleton in a number of cell types (21), how this contributes to Pyk2 phosphorylation is not clear. Phosphorylation of Pyk2 on Y402 may involve
Pyk2 dimerization and subsequent transphosphorylation (51). Rap-dependent actin polymerization could create a cytoskeletal platform that promotes Pyk2 dimerization. However, we found that treating B cells with the actin stabilizing agent jasplakinolide also prevented tyrosine phosphorylation of Pyk2, indicating that polymerized F-actin is not sufficient to support receptor-induced Pyk2 phosphorylation. Dynamic remodeling of the actin cytoskeleton may be required for efficient Pyk2 dimerization. Alternatively, Pyk2-dependent phosphorylation in vivo may require cycles of actin polymerization and depolymerization that regulate either the kinase activity of Pyk2 or the accessibility of its catalytic site.

In contrast to Pyk2, Rap activation and actin dynamics were required for integrin-induced FAK phosphorylation but not for BCR-induced FAK phosphorylation in A20 B lymphoma cells. For integrin-induced FAK phosphorylation, Rap activation was required for the initial step in FAK activation, phosphorylation of Y397, an event that is initiated by transphosphorylation and which can be amplified by SFK (56). How Rap activation and F-actin contribute to integrin-induced FAK Y397 phosphorylation is not clear. Our microscopy data suggest that FAK constitutively co-localizes with integrins in B cells. Rap activation and actin polymerization could therefore contribute to the recruitment and/or stabilization of other proteins that regulate FAK Y397 phosphorylation. In adherent cells that form focal adhesions, integrin activation results in the recruitment of talin to the integrin α and β chain cytoplasmic domains (57). This allows FAK to interact with paxillin and undergo autophosphorylation. At the same time, activation of SFKs by PTPα increases the phosphorylation of FAK at Y397. Further work is required to determine if Rap and F-actin promote integrin-dependent FAK phosphorylation by regulating these steps in B cells. Interestingly, Rap activation and F-actin were not required for BCR-induced phosphorylation of FAK when the cells were in suspension, a situation in which there is minimal integrin engagement. FAK has been reported to associate constitutively with the SFK Lyn and with the BCR in WEHI-231 B lymphoma cells (33). FAK phosphorylation could therefore be a proximal Rap-independent BCR signaling event that is initiated by BCR.

A key finding was that Pyk2 and FAK are important for B cell spreading that is initiated by BCR/integrin co-stimulation or by integrin clustering. This is consistent with Pyk2 and FAK being downstream targets of Rap, since blocking Rap activation also prevents B cell spreading (6,17). Knocking down the expression of either Pyk2 or FAK in A20 B lymphoma cells reduced the ability of these cells to undergo cell spreading whereas PF-431396, a dual specificity inhibitor of the kinase activities of both Pyk2 and FAK, substantially inhibited A20 cell spreading. This suggests that both Pyk2 and FAK contribute to the ability of A20 B lymphoma cells to undergo cell spreading. Moreover, the use of PF-431396 showed that the kinase activities of Pyk2 and FAK were critical for B cell spreading.

Although it is not known how Pyk2 and FAK promote B cell spreading, these kinases may coordinate the activation of Rac, Cdc42, and RhoA, GTPases that control cytoskeletal organization. In T lymphocytes, Pyk2 binds Vav (50), an exchange factor that activates Rac. Both Pyk2 and FAK can interact with the RhoA activator p190RhoGEF (58) and in fibroblasts Pyk2 associates with Wrch1, a Cdc42-like GTPase that promotes the formation of filopodia (59). Pyk2 and FAK can also bind the p85 subunit of phosphoinositide 3-kinase following integrin ligation (60,61). Phosphatidylinositol 3,4,5-trisphosphate produced by phosphoinositide 3-kinase activates Vav and promotes Rac-dependent actin polymerization and cytoskeletal rearrangement. Pyk2 and FAK can also bind and phosphorylate the scaffolding proteins p130Cas and paxillin, which can then recruit the Rac activators DOCK180 and PIX, leading to Rac-dependent membrane ruffling (61).

An interesting observation was that when B cells were activated with LPS plus IL-4, Pyk2 levels decreased but FAK levels increased significantly. B cells activated in this manner resemble antigen-activated germinal center (GC) B cells, which proliferate within lymphoid organ follicles and undergo somatic hypermutation of their Ig genes. These GC B cells then compete for limiting amounts of antigen that are displayed on the surface of FDCs, which provide the B cells with survival signals. GC B cells interacting with FDCs in vivo exhibit a spread morphology with...
multiple membrane processes (62,63). This presumably increases their ability to detect antigens on the surface of the FDC. The activation-induced increase in FAK expression may reflect a switch from the motile phenotype of a circulating B cell to the more adhesive phenotype of an activated GC B cell. FAK expression and activation is associated with sustained adhesion, at least in B cell progenitors (34). A number of adhesion molecules including α6 integrin are upregulated in activated GC B cells (64,65), and gene expression profiling has shown that fak mRNA levels are elevated in GC B cells (66). Thus, the increased expression of FAK after B cell activation may be part of a pro-adhesion gene expression program in which FAK promotes integrin-dependent adhesion and cell spreading, which facilitates BCR-antigen interactions that provide survival signals for GC B cells. Similarly, the change in Pyk2 mRNA splicing in activated B cells may allow Pyk2 to interact with additional proteins that control cell adhesion or cytoskeletal reorganization.

In summary, we have shown that Pyk2 and FAK are downstream targets of the Rap GTPases that play an important role in B cell spreading, a process that contributes to B cell activation.

**Acknowledgments:** We thank Sonja Christian (University of British Columbia) for technical assistance, Dr. Dorothee von Laer (Georg-Speyer Haus, Frankfurt, Germany) for providing the pCMV-ΔR8.91 and pCMV-VSV-G-M5 plasmids, and Dr. Hanne Ostergaard (University of Alberta) and Dr. Michael Schaller (University of North Carolina) for advice and reagents.
References

1. Dal Porto, J. M., Gauld, S. B., Merrell, K. T., Mills, D., Pugh-Bernard, A. E., and Cambier, J. (2004) Mol. Immunol. 41, 599-613
2. Kurosaki, T. (2002) Nat. Rev. Immunol. 2, 354-363
3. Niirro, H., and Clark, E. A. (2002) Nat. Rev. Immunol. 2, 945-956
4. Spaargaren, M., Beuling, E. A., Rurup, M. L., Meijer, H. P., Klok, M. D., Middendorp, S., Hendriks, R. W., and Pals, S. T. (2003) J. Exp. Med. 198, 1539-1550
5. Harris, E. S., McIntyre, T. M., Prescott, S. M., and Zimmerman, G. A. (2000) J. Biol. Chem. 275, 23409-23412
6. Lin, K. B., Freeman, S. A., Zabetian, S., Brugger, H., Weber, M., Lei, V., Dang-Lawson, M., Tse, K. W., Santamaria, R., Batista, F. D., and Gold, M. R. (2008) Immunity 28, 75-87
7. Westerberg, L., Greicius, G., Snapper, S. B., Aspenstrom, P., and Severinson, E. (2001) Blood 98, 1086-1094
8. Bergtold, A., Desai, D. D., Gavhane, A., and Clynes, R. (2005) Immunity 23, 503-514
9. Qi, H., Egen, J. G., Huang, A. Y., and Germain, R. N. (2006) Science 312, 1672-1676
10. Bajenoff, M., Egen, J. G., Koo, L. Y., Laugier, J. P., Brau, F., Glaichenhaus, N., and Germain, R. N. (2006) Immunity 25, 989-1001
11. Fleire, S. J., Goldman, J. P., Carrasco, Y. R., Weber, M., Bray, D., and Batista, F. D. (2006) Science 312, 738-741
12. Carrasco, Y. R., Fleire, S. J., Cameron, T., Dustin, M. L., and Batista, F. D. (2004) Immunity 20, 589-599
13. Carrasco, Y. R., and Batista, F. D. (2006) EMBO J. 25, 889-899
14. Rovida, E., Lugli, B., Barbetti, V., Giuntoli, S., Olivotto, M., and Dello Sbarba, P. (2005) Biol. Chem. 386, 919-929
15. van Buul, J. D., Anthony, E. C., Fernandez-Borja, M., Burridge, K., and Hordijk, P. L. (2005) J. Biol. Chem. 280, 21129-21136
16. Okigaki, M., Davis, C., Falasca, M., Harroch, S., Felsenfeld, D. P., Sheetz, M. P., and Schlessinger, J. (2003) Proc. Natl. Acad. Sci. USA 100, 10740-10745
17. Andreev, J., Simon, J. P., Sabatini, D. D., Kam, J., Plowman, G., Randazzo, P. A., and Schlessinger, J. (1999) Mol. Cell. Biol. 19, 2338-2350
18. Gismondi, A., Jacobelli, J., Strippoli, R., Mainiero, F., Soriani, A., Cifaldi, L., Piccoli, M., Frati, L., and Santoni, A. (2003) J. Immunol. 170, 3065-3073
19. Lakkakorpi, P. T., Bett, A. J., Lipfert, L., Rodan, G. A., and Duong Le, T. (2003) J. Biol. Chem. 278, 11502-11512
20. Sieg, D. J., Ilic, D., Jones, K. C., Damsky, C. H., Hunter, T., and Schlaepfer, D. D. (1998) EMBO J. 17, 5933-5947
29. Astier, A., Avraham, H., Manie, S. N., Groopman, J., Canty, T., Avraham, S., and Freedman, A. S. (1997) *J. Biol. Chem.* **272**, 228-232
30. Freedman, A. S., Rhynhart, K., Nojima, Y., Svahn, J., Eliseo, L., Benjamin, C. D., Morimoto, C., and Vivier, E. (1993) *J. Immunol.* **150**, 1645-1652
31. Manie, S. N., Astier, A., Wang, D., Phifer, J. S., Chen, J., Lazarovits, A. I., Morimoto, C., and Freedman, A. S. (1996) *Blood* **87**, 1855-1861
32. Glodek, A. M., Honczarenko, M., Le, Y., Campbell, J. J., and Silberstein, L. E. (2003) *J. Exp. Med.* **197**, 461-473
33. Mlinaric-Rascan, I., and Yamamoto, T. (2001) *FEBS Lett.* **498**, 26-31
34. Glodek, A. M., Honczarenko, M., Le, Y., Campbell, J. J., and Silberstein, L. E. (2003) *J. Exp. Med.* **197**, 461-473
35. Mlinaric-Rascan, I., and Yamamoto, T. (2001) *FEBS Lett.* **498**, 26-31
36. Lafuente, E. M., van Puijenbroek, A. A., Krause, M., Carman, C. V., Freeman, G. J., Berezovskaya, A., Constantine, E., Springer, T. A., Gertler, F. B., and Boussiotis, V. A. (2004) *Dev. Cell* **7**, 585-595
37. Han, J., Lim, C. J., Watanabe, N., Soriani, A., Ratnikov, B., Calderwood, D. A., Puzon-McLaughlin, W., Lafuente, E. M., Boussiotis, V. A., Shattil, S. J., and Ginsberg, M. H. (2006) *Curr. Biol.* **16**, 1796-1806
38. Bos, J. L. (2005) *Curr. Opin. Cell Biol.* **17**, 123-128
39. Miyake, K., Weissman, I. L., Greenberger, J. S., and Kincade, P. W. (1991) *J. Exp. Med.* **173**, 599-607
40. Buckbinder, L., Crawford, D. T., Qi, H., Ke, H. Z., Olson, L. M., Long, K. R., Bonnette, P. C., Baumann, A. P., Hambor, J. E., Grassner, W. A., 3rd, Pan, L. C., Owen, T. A., Luzzio, M. J., Huford, C. A., Gebhard, D. F., Paralkar, V. M., Simmons, H. A., Kath, J. C., Roberts, W. G., Smock, S. L., Guzman-Perez, A., Brown, T. A., and Li, M. (2007) *Proc. Natl. Acad. Sci. USA* **104**, 10619-10624
41. Durand, C. A., Westendorf, J., Tse, K. W., and Gold, M. R. (2006) *Immunol. Res.* **36**, 2235-2249
42. McLeod, S. J., Li, A. H., Lee, R. L., Burgess, A. E., and Gold, M. R. (2002) *J. Immunol.* **169**(3), 1365-1371
43. Freundlich, B., and Avdalovic, N. (1983) *J. Immunol. Meth.* **62**, 31-37
44. Yee, J. K., Friedmann, T., and Burns, J. C. (1994) *Meth. Cell Biol.* **43**, 99-112
45. Naldini, L., Blomer, U., Gallay, P., Dang, A. E., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996) *Science* **272**, 263-267
46. Santos-Argumedo, L., Kincade, P. W., Partida-Sanchez, S., and Parkhouse, R. M. (1997) *Immunol.* **90**, 147-153
47. Elenstrom, C., and Severinson, E. (1989) *Growth Factors* **2**, 73-82
48. Davey, E. J., Thyberg, J., Conrad, D. H., and Severinson, E. (1998) *J. Immunol.* **160**, 5366-5373
49. Xiong, W. C., Macklem, M., and Parsons, J. T. (1998) *J. Cell Sci.* **111**, 1951-1991
50. Ostergaard, H. L., and Lysechko, T. L. (2005) *Immunol. Res.* **31**, 267-282
51. Park, S. Y., Avraham, H. K., and Avraham, S. (2004) *J. Biol. Chem.* **279**, 33315-33322
52. Christian, S. L., Lee, R. L., McLeod, S. J., Burgess, A. E., Li, A. H., Dang-Lawson, M., Lin, K. B., and Gold, M. R. (2003) *J. Biol. Chem.* **278**, 41756-41767
53. Mochizuki, N., Ohba, Y., Kiyokawa, E., Kurata, T., Murakami, T., Ozaki, T., Kitabatake, A., Nagashima, K., and Matsuda, M. (1999) *Nature* **400**, 891-894
54. Ohba, Y., Mochizuki, N., Matsuo, K., Yamashita, S., Nakaya, M., Hashimoto, Y., Hamaguchi, M., Kurata, T., Nagashima, K., and Matsuda, M. (2000) *Mol. Cell. Biol.* **20**, 6074-6083
55. Bubb, M. R., Senderowicz, A. M., Sausville, E. A., Duncan, K. L., and Korn, E. D. (1994) *J. Biol. Chem.* **269**, 14869-14871
56. Zeng, L., Si, X., Yu, W. P., Le, H. T., Ng, K. P., Teng, R. M., Ryan, K., Wang, D. Z., Ponniiah, S., and Pallen, C. J. (2003) *J. Cell Biol.* **160**, 137-146
57. Schlaepfer, D. D., Mitra, S. K., and Ilic, D. (2004) *Biochim. Biophys. Acta* **1692**, 77-102
58. Lim, Y., Lim, S. T., Tomar, A., Gardel, M., Bernard-Trifilo, J. A., Chen, X. L., Uryu, S. A., Canete-Soler, R., Zhai, J., Lin, H., Schlaepfer, W. W., Nalbant, P., Bokoch, G., Ilic, D., Waterman-Storer, C., and Schlaepfer, D. D. (2008) *J. Cell Biol.* **180**, 187-203

59. Ruusala, A., and Aspenstrom, P. (2008) *Mol. Cell. Biol.* **28**, 1802-1814

60. Sarkar, S., Svoboda, M., de Beaumont, R., and Freedman, A. S. (2002) *Leuk. Lymphoma* **43**, 1663-1671

61. Mitra, S. K., Hanson, D. A., and Schlaepfer, D. D. (2005) *Nat. Rev. Mol. Cell Biol.* **6**, 56-68

62. Allen, C. D., Okada, T., Tang, H. L., and Cyster, J. G. (2007) *Science* **315**, 528-531

63. Hauser, A. E., Junt, T., Mempel, T. R., Sneddon, M. W., Klein, S. H., Henrickson, S. E., von Andrian, U. H., Shlomchik, M. J., and Haberman, A. M. (2007) *Immunity* **26**, 655-667

64. Ambrose, H. E., and Wagner, S. D. (2004) *Immunol.* **111**, 400-406

65. Klein, U., Tu, Y., Stolovitzky, G. A., Keller, J. L., Haddad, J., Jr., Miljkovic, V., Cattoretti, G., Califano, A., and Dalla-Favera, R. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 2639-2644

66. Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., Powell, J. I., Yang, L., Marti, G. E., Moore, T., Hudson, J., Jr., Lu, L., Lewis, D. B., Tibshirani, R., Sherlock, G., Chan, W. C., Greiner, T. C., Weisenburger, D. D., Armitage, J. O., Warnke, R., Levy, R., Wilson, W., Grever, M. R., Byrd, J. C., Botstein, D., Brown, P. O., and Staudt, L. M. (2000) *Nature* **403**, 503-511

67. Robertson, L. K., Mireau, L. R., and Ostergaard, H. L. (2005) *J. Immunol.* **175**, 8138-8145

68. Cai, X., Li, M., Vrana, J., and Schaller, M. D. (2006) *Mol. Cell. Biol.* **26**, 2857-2868
Footnotes

*This work was supported by operating grant #68865 (to M.R.G) from the Canadian Institutes of Health Research and by graduate student fellowships (to K.W.K.T) from the Michael Smith Foundation for Health Research and the Natural Sciences and Engineering Research Council of Canada.

1To whom correspondence should be addressed: 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Tel.: 604-822-4070; FAX: 604-822-6041; E-mail: mgold@interchange.ubc.ca.

2Abbreviations used: Ab, antibody; BCR, B cell receptor; Ig, immunoglobulin; FDC, follicular dendritic cell; FRC, fibroblastic reticular cell; ECM, extracellular matrix; ICAM-1, intercellular adhesion molecule-1; LFA-1, lymphocyte function-associated antigen-1; TCR, T cell receptor; Pyk2, proline-rich tyrosine kinase; FAK, focal adhesion kinase; VLA-4, very late antigen-4; P-Tyr, phosphotyrosine; LPS, lipopolysaccharide; FCS, fetal calf serum; PBS, phosphate-buffered saline; shRNA, short hairpin RNA; SFK, Src family kinase; GC, germinal center.
Figure legends

FIGURE 1. Expression and localization of Pyk2 and FAK in B cells. A, Pyk2 and FAK protein levels in cell lysates (40 μg protein) from A20 B lymphoma cells, resting splenic B cells, and splenic B cells that were activated with LPS plus IL-4 for 2 days were analyzed by sequential blotting with Abs to Pyk2, FAK, and Erk1/2 (loading control). Molecular mass markers (in kDa) are indicated to the right of each blot. The relative amount of Pyk2 or FAK protein in activated B cells, compared to resting B cells (=1), was determined by quantifying band intensities with ImageJ and normalizing the values to the amount of Erk in the sample. The data represent the mean ± SEM for three independent experiments. B, The relative amounts of pyk2 and fak mRNA in resting and activated splenic B cells were determined by quantitative RT-PCR. Values were normalized to the amount of gapdh mRNA in the same sample and are expressed as the amount of mRNA (average ± range for two independent experiments) relative to that in resting B cells (=1). C, Resting and LPS/IL-4-activated splenic B cells were left unstimulated for 30 min (-) or were incubated with 10 μg/ml anti-IgM Abs for 30 min. Anti-Pyk2 immunoprecipitates were analyzed by blotting with the 4G10 anti-P-Tyr antibody (upper panel). The blots were then stripped and reprobed with an Ab to Pyk2 (lower panel). One of two experiments that yielded similar results is shown. D, RT-PCR analysis of alternatively spliced pyk2 mRNA in resting splenic B cells and LPS/IL-4-activated B cells. PCR primers flanking the alternatively spliced exon distinguish the full-length mRNA from the spliced isoform, which is 126 bp shorter. Data are representative of three experiments with similar results. E, Resting and LPS/IL-4-activated splenic B cells were permeabilized and stained with goat anti-Pyk2 or goat anti-FAK plus Alexa488-conjugated secondary Ab. Nuclei were visualized with DAPI (blue). No fluorescence was observed when the cells were stained with secondary Ab alone, or with non-specific goat IgG plus secondary Ab (supplemental Fig. 1). F, LPS/IL-4 activated splenic B cells were permeabilized and stained with Abs to FAK plus Abs to either LFA-1 or VLA-4. In E and F, each panel shows representative data from one of three experiments with similar results.

FIGURE 2. Adhesion of B cells to ECM selectively enhances BCR-induced tyrosine phosphorylation of Pyk2 and FAK. A20 cells were kept in suspension or plated on collagen/fibronectin ECM for 30 min before being stimulated with 20 μg/ml soluble anti-IgG for the indicated times. For unstimulated controls (-), A20 cells were kept in suspension or plated on collagen/fibronectin ECM for 30 min and then left unstimulated for an additional 45 min before being lysed. A, Immunoprecipitated Pyk2 and FAK were analyzed by immunoblotting with the 4G10 anti-P-Tyr Ab. The blots were then reprobed with Abs to Pyk2 or FAK. A mock stimulation of cells with PBS for 15 or 30 min did not increase phosphorylation of Pyk2 and FAK, compared to cells left unstimulated for the entire duration of the experiment (supplemental Fig. 2). B, Cell lysates were immunoblotted with Abs against the phosphorylated forms of Erk (P-Erk) or Akt (P-Akt) and then reprobed with Abs against total Erk or Akt. C, Cell lysates were immunoblotted with a paxillin Ab. Serine/threonine phosphorylation of paxillin is indicated by a bandshift on SDS-PAGE gels and was dependent on the activity of the Erk and GSK-3 kinases (data not shown), as in T cells and macrophages (67,68). For each panel, similar results were obtained in three experiments. αIgG, anti-IgG Ab; ECM, extracellular matrix.

FIGURE 3. A20 cell spreading involves both Pyk2 and FAK. Lentiviral transduction was used to establish stable bulk populations of A20 cells expressing the GFP-encoding pGIPZ vector or derivates encoding a Pyk2-specific shRNA or a FAK-specific shRNA. A, Representative FACS plots showing GFP expression by the transduced A20 cells (solid lines), compared to untransduced parental A20 cells (shaded curves). The percent of transduced cells that were GFP+ is indicated. B, Immunoblot analysis of Pyk2 and FAK protein levels in cell lysates (40 μg protein per lane). The Pyk2 and FAK blots were reprobed with Abs to actin (loading control). C, A20 cells transduced with the pGIPZ vector, Pyk2 shRNA, or FAK shRNA were plated on wells coated with 2.63 μg/cm² fibronectin and then stimulated with 10 μg/ml soluble anti-IgG for 4 h (upper panels) or were plated on wells coated with 2.63 μg/cm² fibronectin.
anti-LFA-1 Abs for 4 h (bottom panels). Representative images are shown. D, The percent of adherent A20 cells that had spread after 2 or 4 h, as indicated by being phase dark with an elongated or irregular shape, was determined. The data are presented as the average ± SEM for >300 cells counted in each of three experiments. *, p <0.05, **, p <0.01 by Student’s one-tailed paired t-test, compared to vector control cells. αIgG, anti-IgG Abs; αLFA-1, anti-LFA-1 Ab; FN, fibronectin.

FIGURE 4. BCR/integrin-induced tyrosine phosphorylation of Pyk2 and FAK depends on activation of the Rap GTPases. Vector control and RapGAPII-expressing A20 cells were cultured for 30 min in wells coated with collagen/fibronectin ECM before being stimulated with 20 μg/ml anti-IgG for the indicated times. For unstimulated controls (-), A20 cells were plated on collagen/fibronectin ECM for 30 min and then left unstimulated for another 30 min before being lysed. A, Anti-Pyk2 immunoprecipitates were probed with an Ab against Pyk2 that is phosphorylated on Y402 (anti-pY402), or with the 4G10 anti-P-Tyr Ab, before being reprobed with an anti-Pyk2 Ab. B, Anti-FAK immunoprecipitates were probed with an Ab that recognizes FAK that is phosphorylated on Y397 (anti-pY397), or with the 4G10 anti-P-Tyr Ab, before being reprobed with an anti-FAK Ab. C, Anti-FAK immunoprecipitates were probed sequentially with Abs that recognize FAK that is phosphorylated on either Y576 or Y577 before being reprobed with an anti-FAK Ab. The relative levels of Pyk2 and FAK phosphorylation were determined by quantifying band intensities using ImageJ, normalizing the values to the total amount of Pyk2 or FAK in the same lane, and expressing the values (mean ± SEM for three experiments) relative to the Pyk2 or FAK phosphorylation levels in unstimulated vector control cells (= 1). *, p <0.05 by Student’s one-tailed paired t-test.

FIGURE 5. Rap activation is important for integrin-induced phosphorylation of Pyk2 and FAK. Vector control and RapGAPII-expressing A20 cells were plated in wells coated with 3.5 μg/cm² anti-CD40 (control), anti-LFA-1, or anti-VLA-4 monoclonal Abs for 15 or 30 min. Anti-Pyk2 (A) and anti-FAK (B) immunoprecipitates were analyzed by blotting with the 4G10 anti-P-Tyr Ab. The blots were then stripped and reprobed with Abs against Pyk2 or FAK. For FAK phosphorylation, band intensities were normalized to the amount of total FAK for each sample and then expressed as the relative phosphorylation (mean ± SEM for three experiments) compared to that for vector control cells plated on anti-CD40 (= 1). *, p <0.05 by Student’s one-tailed paired t-test.

FIGURE 6. Rap activation is important for BCR-induced tyrosine phosphorylation of Pyk2 but not FAK. Vector control and RapGAPII-expressing A20 cells were stimulated in suspension with 20 μg/ml anti-IgG for the indicated times. For unstimulated controls (-), A20 cells were left in suspension for 30 min without being stimulated. A, Anti-Pyk2 immunoprecipitates were probed with either the 4G10 anti-P-Tyr Ab, an Ab against Pyk2 that is phosphorylated on Y402, or an Ab against Pyk2 that is phosphorylated on Y579/Y580. The blots were then stripped and reprobed with a Pyk2 Ab. B, Anti-FAK immunoprecipitates were probed with either the 4G10 anti-P-Tyr Ab or an Ab against FAK that is phosphorylated on Y397. The blots were then stripped and reprobed with a FAK Ab. Band intensities were normalized to the amount of total Pyk2 or FAK for each sample and then expressed as the relative phosphorylation (mean ± SEM for three experiments) compared to that for unstimulated vector control cells (= 1). *, p <0.05 by Student’s one-tailed paired t-test. The values for FAK phosphorylation in vector and RapGAPII-expressing cells were not significantly different by this test.

FIGURE 7. Rap-dependent phosphorylation of Pyk2 and FAK requires actin dynamics. A20 cells in suspension or plated on ECM were pre-treated with 10 μM latrunculin A or an equivalent volume of DMSO for 30 min before being stimulated with 20 μg/ml soluble anti-IgG for the indicated times. For unstimulated controls (-), A20 cells were kept in suspension or plated on collagen/fibronectin ECM for 30 min and then left unstimulated for another 30 min before being lysed. A, Anti-Pyk2 immunoprecipitates were sequentially probed with an Ab that recognizes Pyk2 that is phosphorylated at Y402, an Ab that recognizes Pyk2 that is phosphorylated at Y579/Y580, the 4G10 anti-P-Tyr Ab, and an
anti-Pyk2 Ab.  B, Cell lysates were assayed for phosphorylation of Akt and Erk as in Figure 2B.  C, A GST-RalGDS fusion protein was used to selectively precipitate the active GTP-bound form of Rap1, which was detected by immunoblotting with a Rap1 Ab (upper panel). The lower panel shows the amount of Rap1 in the cell lysates.  D, Tyrosine phosphorylation of FAK was assessed by blotting anti-FAK immunoprecipitates with the 4G10 anti-P-Tyr Ab and then reprobing with an anti-FAK Ab.  FAK phosphorylation (mean ± SEM for three experiments) relative to that in unstimulated DMSO-treated cells kept in suspension (= 1) is graphed.  *, p <0.05 by Student’s one-tailed paired t-test.  E, A20 cells in suspension were pre-treated with 1 μM jasplakinolide or an equivalent volume of DMSO for 30 min before being stimulated with 20 μg/ml anti-IgG for the indicated times or being left unstimulated for 30 min (-).  Pyk2 and FAK tyrosine phosphorylation, as well as Rap1 activation, was assessed.  For each panel, similar results were obtained in three experiments.  Lat A, latrunculin A; Jas, jasplakinolide.

FIGURE 8.  An inhibitor of Pyk2/FAK activity blocks B cell spreading.  A, A20 cells in suspension were treated with the indicated concentrations of PF-431396 or with DMSO for 45 min before being stimulated with 20 μg/ml anti-IgG for 20 min.  For unstimulated controls (-), A20 cells were kept in suspension for 45 min and then left unstimulated for another 20 min before being lysed.  Pyk2 and FAK immunoprecipitates were analyzed by blotting with the 4G10 anti-P-Tyr Ab (left panel) before being reprobed with Abs against Pyk2 or FAK.  The same cell lysates were analyzed for total tyrosine phosphorylation using the 4G10 anti-P-Tyr Ab and for Erk phosphorylation (right panel).  B, A20 cells were treated with PF-431396 or DMSO for 45 min.  The cells were then added to fibronectin/collagen ECM-coated wells and stimulated for 30 min with soluble anti-Ig.  Alternatively, the cells were added to wells coated with 2.63 μg/cm² anti-LFA-1 Abs for 30 min.  Pyk2 and FAK immunoprecipitates were analyzed by blotting with the 4G10 anti-P-Tyr Ab.  C, A20 cells were plated on wells coated with 2.63 μg/cm² fibronectin and stimulated with 10 μg/ml anti-IgG in the presence of DMSO or 2.5 μM PF-431396 for 1, 2, or 4 h. Representative images of the 4 h time point are shown.  D, A20 cells were plated on wells coated with 2.63 μg/cm² anti-LFA-1 Ab in the presence of DMSO or 2.5 μM PF-431396 for 1 h or 3 h. Representative images of the 3 h time point are shown.  Cell surface expression of LFA-1 was not affected by PF-431396 treatment (data not shown).  The percent of adherent A20 cells that had spread (mean ± SEM for >150 cells counted in each of three experiments), as indicated by being phase dark with an elongated or irregular shape, was determined for each time point.  *, p <0.05 by Student’s one-tailed paired t-test, compared to DMSO-treated cells.
Fig. 1

A

Pyk2
FAK
Erk

Relative level of Pyk2 protein

Relative level of FAK protein

B

Normalized relative level of Pyk2 mRNA

Normalized relative level of FAK mRNA

C

|    | Resting B cells | LPS/IL-4-activated B cells |
|----|----------------|----------------------------|
| α IgM (min) | - 30 | - 30 |
| Pyk2 ippt | 97 |
| P-Tyr blot | 110 |
| Pyk2 reprobe | 45 |

D

(unsliced form) 738 bp
(spliced form) 612 bp

E

Resting splenic B cells
LPS/IL-4-activated B cells

5 μm

F

FAK LFA-1 FAK+LFA-1 +DAPI

LPS/IL-4 activated B cells

5 μm
Fig. 2

A

Stimulus: soluble IgG

|        | Suspension | ECM  |
|--------|------------|------|
| IgG (min) | - 15 30 45 | - 15 30 45 |
| Pyk2 ippt |            | 97   |
| P-Tyr blot |           |      |
| Pyk2 reprobe |       |      |
| FAK ippt |            | 110  |
| P-Tyr blot |           |      |
| FAK reprobe |         |      |

B

Stimulus: soluble IgG

|        | Suspension | ECM  |
|--------|------------|------|
| IgG (min) | - 15 30 45 | - 15 30  |
| P-Erk blot |           | 45   |
| Erk reprobe |          |      |
| P-Akt blot |            | 66   |
| Akt reprobe |          |      |

C

Stimulus: soluble IgG

|        | Suspension | ECM  |
|--------|------------|------|
| IgG (min) | - 15 30 45 | - 15 30  |
| Paxillin blot |        | 66   |

JBC
Fig. 3

A

| Untransfected pGIPZ vector | Untransfected Pyk2 shRNA | Untransfected FAK shRNA |
|-----------------------------|--------------------------|-------------------------|

% of max

B

Pyk2 blot
Actin reprobe
FAK blot
Actin reprobe

C

pGIPZ
Pyk2 shRNA
FAK shRNA

αlg+FN

αLFA-1

30 µm

D

Spreading (% of adherent cells)

FN+αlg 2h

4h

αLFA-1 2h

4h
Fig. 4

A

| Stimulus: soluble IgG on ECM | Vector | RapGAPII |
|-------------------------------|--------|----------|
| IgG (min)                     | 15     | 15       |
| Pyk2 iptt                     |        |          |
| P-Tyr blot                    |        |          |
| Pyk2 reprobe                  |        |          |

B

| Stimulus: soluble IgG on ECM | Vector | RapGAPII |
|-------------------------------|--------|----------|
| IgG (min)                     | 15     | 15       |
| FAK iptt                      |        |          |
| P397 blot                     |        |          |
| FAK reprobe                   |        |          |

C

| Stimulus: soluble IgG on ECM | Vector | RapGAPII |
|-------------------------------|--------|----------|
| IgG (min)                     | 15     | 15       |
| FAK iptt                      |        |          |
| P576 blot                     |        |          |
| pFAK iptt                     |        |          |
| Pyk2 reprobe                  |        |          |

Normalized FAK Y402 phosphorylation

Normalized FAK Y397 phosphorylation

Normalized FAK Y576 phosphorylation

Normalized FAK Y577 phosphorylation
Fig. 5

A

|                  | Vector   | RapGAPII |
|------------------|----------|----------|
| αCD40 30'        | 15       | 15       |
| αLFA-1 15'       | 30       | 15'      |
| αVLA-4 30'       | 15'      | 30       |

Pyk2 ippt

P-Tyr blot

Pyk2 reprobe

B

|                  | Vector   | RapGAPII |
|------------------|----------|----------|
| αCD40 30'        | 15       | 15       |
| αLFA-1 15'       | 30       | 15'      |
| αVLA-4 30'       | 15'      | 30       |

FAK ippt

P-Tyr blot

FAK reprobe

Normalized FAK tyrosine phosphorylation

- □ Vector
- ■ RapGAPII

* *
Fig. 6

**A**

| Stimulus: soluble αIgG |
|------------------------|
| αIgG (min)             |
| Vector                 |
| RapGAPII               |
| Pyk2 ippt              |
| P-Tyr blot            |
| Pyk2 reprobe          |

| Stimulus: soluble αIgG |
|------------------------|
| αIgG (min)             |
| Vector                 |
| RapGAPII               |
| Pyk2 ippt              |
| pY402 blot            |
| Pyk2 reprobe          |

| Stimulus: soluble αIgG |
|------------------------|
| αIgG (min)             |
| Vector                 |
| RapGAPII               |
| Pyk2 ippt              |
| pY579/580 blot        |
| Pyk2 reprobe          |

**B**

| Stimulus: soluble αIgG |
|------------------------|
| αIgG (min)             |
| Vector                 |
| RapGAPII               |
| FAK ippt               |
| P-Tyr blot            |
| FAK reprobe           |

| Stimulus: soluble αIgG |
|------------------------|
| αIgG (min)             |
| Vector                 |
| RapGAPII               |
| FAK ippt               |
| pY397 blot            |
| FAK reprobe           |

---

Normalized Pyk2 Y402 phosphorylation

Vector
RapGAPII

Normalized Pyk2 Y579/580 phosphorylation

Vector
RapGAPII

Normalized FAK Y397 phosphorylation

Vector
RapGAPII
Fig. 7

A

|                | Soluble αIgG | αIgG + ECM |
|----------------|--------------|------------|
| αIgG (min)     | Lat A        | Lat A      |
| Pyk2 ippt      | - 15 30      | - 15 30    |
| pY402 blot     |              |            |
| pY579/580 blot |              |            |
| P-Tyr blot     |              |            |
| Pyk2 reprobe   |              |            |

B

|                | Soluble αIgG | αIgG + ECM |
|----------------|--------------|------------|
| αIgG (min)     | Lat A        | Lat A      |
| P-Akt blot     | - 15 30      | - 15 30    |
| Akt reprobe    |              |            |
| P-Erk blot     |              |            |
| Erk reprobe    |              |            |

C

|                | Soluble αIgG | αIgG + ECM |
|----------------|--------------|------------|
| αIgG (min)     | Lat A        | Lat A      |
| Rap1-GTP       | - 15 30      | - 15 30    |
| Total Rap      |              |            |

D

|                | Soluble αIgG | αIgG + ECM |
|----------------|--------------|------------|
| αIgG (min)     | Lat A        | Lat A      |
| FAK ippt       | - 15 30      | - 15 30    |
| P-Tyr blot     |              |            |
| FAK reprobe    |              |            |

E

|                | DMSO | Jas |
|----------------|------|-----|
| αIgG (min)     | - 15 | 15 30 |
| Pyk2 ippt      |      |      |
| P-Tyr blot     |      |      |
| Pyk2 reprobe   |      |      |

|                | DMSO | Jas |
|----------------|------|-----|
| αIgG (min)     | 5    | 15 30 |
| Rap1-GTP       |      |      |
| Total Rap      |      |      |

*Denotes statistically significant difference compared to control.
Fig. 8

A

| Inhibitor | DMSO | PF-431396 (µM) |
|-----------|------|----------------|
| Stimulation | - | IgG 20' |
| Pyk2 ippt | - | 97 |
| P-Tyr blot | - | 110 |
| Pyk2 reprobe | - | |
| FAK ippt | - | |
| P-Tyr blot | - | |
| FAK reprobe | - | |

B

| Inhibitor | DMSO | PF-431396 (µM) |
|-----------|------|----------------|
| Stimulation | - | IgG 20' |
| Soluble IgG + ECM | - | 97 |
| αLFA-1 | - | 110 |
| Pyk2 ippt | 30 | 30 |
| P-Tyr blot | 30 | 30 |
| Pyk2 reprobe | 30 | 30 |
| FAK ippt | 30 | 30 |
| P-Tyr blot | 30 | 30 |
| FAK reprobe | 30 | 30 |

C

DMSO

PF - 431396

αIg+FN

D

αLFA-1

Spreading (% of adherent cells)

αIg+FN

1h

2h

4h

DMSO

PF

αLFA-1

1h

9h

DMSO

PF

* *
B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading
Kathy W. K. Tse, May Dang-Lawson, Rosaline L. Lee, Doris Vong, Anica Bulic, Leonard Buckbinder and Michael R. Gold

J. Biol. Chem. published online June 26, 2009

Access the most updated version of this article at doi: 10.1074/jbc.M109.013169

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2009/06/26/M109.013169.DC1